A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma

Hepatology

Volumn 49, Issue 1, 2009, Pages 124-132

  Palmer, Daniel H ^a   Midgley, Rachel S ^a   Mirza, Noweeda ^a   Torr, Elizabeth E ^a   Ahmed, Forhad ^a   Steele, Jane C ^a   Steven, Neil M ^a   Kerr, David J ^a   Young, Lawrence S ^a   Adams, David H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; TUMOR ANTIGEN; CANCER VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL LYSATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FATIGUE; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOSENSITIVITY; VACCINATION; ADOLESCENT; DENDRITIC CELL; IMMUNOLOGY; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; SURVIVAL; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; VACCINATION;

EID: 58949092553     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22626     Document Type: Article

References (36)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
2. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-S188.
3. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. SHARP Investigators Study Group. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007;25(Suppl):LBA1.
4. Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K, et al. Expression and function of CXC and CC chemokines in human malignant liver tumors: A role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. HEPATOLOGY 1999; 30:100-111.
5. Friedl J, Stift A, Paolini P, Roth E, Steger GG, Mader R, et al. Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother Radiopharm 2000;155:477-486.
6. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
7. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-3903.
8. Höltl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999;161:777-782.
9. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006;12:2817-2825.
10. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: A clinical trial. J Immunother 2005;28:496-504.
11. Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y, Kitahara M, Arai K, et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 2007;147:296-305.
12. Butterfield LH. Recent advances in immunotherapy for hepatocellular cancer. Swiss Med Wkly 2007;137:83-90.
13. O'Beirne JP, Harrison PM. The role of the immune system in the control of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:1257-1260.
14. Luo G, Huang S, Xie X, Stockert E, Chen YT, Kubuschok B, et al. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun 2002;2:11.
15. Evdokimova VN, Liu Y, Potter DM, Butterfield LH. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J Immunother 2007;30:425-437.
16. Schuler G, Brang D, Romani N. Production and properties of large numbers of dendritic cells from human blood. Adv Exp Med Biol 1995;378:43-52.
17. Butterfield LH, Ribas A, Potter DM, Economou JS. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother 2007;56: 1931-1943.
18. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004;104:2235-2246.
19. Chen YX, Man K, Ling GS, Chen Y, Sun BS, Cheng Q, et al. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: Superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J Immunol 2007;179:6009-6015.
20. Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 2006;177: 712-721.
21. Cerundolo V, Hermans IF, Salio M. Dendritic cells: A journey from laboratory to clinic. Nat Immunol 2004;5:7-10.
22. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+)regulatory T cells in vivo in humans. Blood 2002;100:174-177.
23. Hanke P, Rabe C, Serwe M, Böhm S, Pagenstecher C, Sauerbruch T, et al. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 2002;37:949-955.
24. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003;9:5902-5908.
25. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003;52:155-161.
26. Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 2004;27: 191-200.
27. Zhang L, Zhang H, Liu W, Wang H, Jia J, Si X, et al. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA. Cell Immunol 2005;238:61-66.
28. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005;28:129-135.
29. Feijoo E, Alfaro C, Mazzolini G, Serra P, Penuelas I, Arina A, et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 2005;116:275-281.
30. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, Vogt A, et al. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. HEPATOLOGY 2008;48:157-168.
31. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ. Dendritic cells: tools and targets for antitumor vaccination. Expert Rev Vaccines 2005;4:699-710.
32. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, et al. Efficient loading of dendritic cells following cryo and radio-frequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006;95:896-905.
33. Sellge G, Lorentz A, Gebhardt T, Levi-Schaffer F, Bektas H, Manns MP, et al. Human intestinal fibroblasts prevent apoptosis in human intestinal mast cells by a mechanism independent of stem cell factor, IL-3, IL-4, and nerve growth factor. J Immunol 2004;172:260-267.
34. Wissniowski TT, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B, et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 2003;63:6496-6500.
35. Geissler M, Mohr L, Weth R, Köhler G, Grimm CF, Krohne TU, et al. Immunotherapy directed against alpha-fetoprotein results in autoimmune liver disease during liver regeneration in mice. Gastroenterology 2001;121: 931-939.
36. Hanke P, Serwe M, Dombrowski F, Sauerbruch T, Caselmann WH. DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther 2002;9:346-355.